Ad5 Ag85A
Alternative Names: Ad5Ag85A; Recombinant genetic TB vaccine Ad5Ag85A; Recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A) - Tianjin CanSino Biotechnology; TB vaccine candidate - Tianjin CanSino Biotechnology/AerasLatest Information Update: 28 Sep 2021
At a glance
- Originator McMaster University
- Developer McMaster University; Tianjin CanSino Biotechnology
- Class Antituberculars; DNA vaccines; Gene therapies; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in Canada (IM, Injection)
- 01 Aug 2018 Phase I development in Tuberculosis (Prevention) is ongoing in Canada (IM) (Aeras Global Clinical TB pipeline, August 2018)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Tuberculosis(Prevention, In volunteers) in Canada (IM, Injection)